A Food and Drug Administration advisory committee last week recommendedapproval of Merck's Fosamax drug for the treatment of osteoporosis.If Fosamax is approved by the FDA, it is expected to give a boostto vendors of dual-energy x-ray absorptiometry
A Food and Drug Administration advisory committee last week recommendedapproval of Merck's Fosamax drug for the treatment of osteoporosis.If Fosamax is approved by the FDA, it is expected to give a boostto vendors of dual-energy x-ray absorptiometry (DEXA) scanners,such as Lunar and Hologic. Merck last month announced financingagreements with the companies to help promote sales of bone densitometrydevices (SCAN 7/6/95).
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.